Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors Related Keratopathy

To report cornea complications in patients using systemic epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKI).

A retrospective case series of patients on systemic EGFR-TKI who presented with keratopathy from January 2015 to December 2020 to Lo Fong Shiu Po Eye Center, Grantham Hospital, Hong Kong SAR.

Case records of patients on systemic EGFR-TKi attending Lo Fong Shiu Po Eye Center, Grantham Hospital, Hong Kong SAR were reviewed. Presenting symptoms, signs, visual acuity were recorded. In case of epithelial defect, time needed to heal was documented. All treatment plans were also reviewed.

A total of six patients on systemic EGFR-TKI presented with keratopathy during the study period. Three patients had severe dry eyes with punctate epithelial erosions, requiring intensive topical lubricants and punctual occlusion. Three patients presented with epithelial defect in one eye, with an average resolution time of 47 days. All patients received topical lubricants and antibiotic prophylaxis, and bandage contact lens. Systemic EGFR-TKI was stopped in two patient due to persistent epithelial defect.

Cornea complications in EGFR-TKI are not uncommon. Early recognition and prompt treatment can prevent permanent visual damage.